Thus , the ability to generate platelet products ex vivo and platelet products lacking HLA antigens in serum - free media would have clinical value .
A significant problem for multitransfused patients is refractoriness to platelet transfusions .
The ability to generate platelet products ex vivo and platelet products lacking HLA antigens in serum - free media would have clinical value .
A significant problem for multitransfused patients is refractoriness to platelet transfusions .